Company intelligence / Profile preview

Immune Oncology Research Institute

Yerevan, Yerevan, Armeniaimmonc.org ↗

Ownership: Private
Employees: ~13
Development stage: Other

Overview

IMMONC has launched several investigator-led studies since its founding in mid–2022. Its most advanced program is a Phase II trial of balstilimab for relapsed/refractory lymphomas. The institute also coordinates an international registry for BPDCN with participation from centers across multiple countries. Preliminary results have been presented at major hematology conferences.

Therapeutic areas: Oncology
Modalities: Immuno-oncology therapies (e.g., immune checkpoint inhibitors like balstilimab)Clinical data generation and registriesInvestigator-led clinical trials
Industry: Academic Hospital/University/Research

Partnerships

Agenus Inc. — collaboration on the balstilimab clinical trial

Beyond the preview

Go deeper on Immune Oncology Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Oncology Research Institute.